Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had received notification from its licensee Global Kinetics, Inc. that the Ministry of Health of the Royal Government of Cambodia had approved the registration of ABI’s natural human low-dose interferon alpha, which will be marketed under the name VELDONA. The official notification, received by Global Kinetics from the Director-General of Technical Health, Dr. Tep Lun, also indicated that Global Kinetics must wait two to three weeks to obtain a provisional certificate allowing the importation of VELDONA for sale in the Kingdom of Cambodia. Global Kinetics has a license and supply agreement for interferon from ABI in the countries of Cambodia, Laos and Vietnam.
